The Limited Times

Now you can see non-English news...

Alzheimer's: a treatment finally slows the disease


DECRYPTION - This monoclonal antibody is the first to have a significant impact on the progression of the disease, but it remains moderate.

By their own admission, it's a beautiful day for neurologists who have been working on Alzheimer's disease for several decades.

This Wednesday were published in the

New England Journal of Medicine

the results of a clinical trial evaluating the effectiveness of a monoclonal antibody, lecanemab, in slowing the progression of the disease.

Even if the effectiveness is measured, and is accompanied by significant adverse effects, this positive effect, unseen for 30 years, opens the way to a new era of treatments, comment the experts.

To discover

  • Prime Macron 2022: conditions, amount, date of payment... how does it work?

Alzheimer's disease is extremely painful for patients and their loved ones in that it is currently impossible to stop its progression until the patient loses his cognitive faculties and his autonomy.

However, lecanemab, co-developed by two laboratories, the Japanese Eisai and the American Biogen, shows for the first time a significant and constant effect on the evolution of the disease.

Read alsoAlzheimer's: genetics opens up new avenues of understanding

Immunotherapy was given for 18 months to…

This article is for subscribers only.

You have 81% left to discover.

Cultivating your freedom is cultivating your curiosity.

Keep reading your article for €0.99 for the first month


Already subscribed?


Source: lefigaro

All business articles on 2022-11-30

You may like

Life/Entertain 2023-01-06T20:18:01.772Z
Business 2023-01-06T19:47:55.852Z

Trends 24h


© Communities 2019 - Privacy